These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 30343896)
1. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Hu H; Mu Q; Bao Z; Chen Y; Liu Y; Chen J; Wang K; Wang Z; Nam Y; Jiang B; Sa JK; Cho HJ; Her NG; Zhang C; Zhao Z; Zhang Y; Zeng F; Wu F; Kang X; Liu Y; Qian Z; Wang Z; Huang R; Wang Q; Zhang W; Qiu X; Li W; Nam DH; Fan X; Wang J; Jiang T Cell; 2018 Nov; 175(6):1665-1678.e18. PubMed ID: 30343896 [TBL] [Abstract][Full Text] [Related]
2. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Bao ZS; Chen HM; Yang MY; Zhang CB; Yu K; Ye WL; Hu BQ; Yan W; Zhang W; Akers J; Ramakrishnan V; Li J; Carter B; Liu YW; Hu HM; Wang Z; Li MY; Yao K; Qiu XG; Kang CS; You YP; Fan XL; Song WS; Li RQ; Su XD; Chen CC; Jiang T Genome Res; 2014 Nov; 24(11):1765-73. PubMed ID: 25135958 [TBL] [Abstract][Full Text] [Related]
3. High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. Huang R; Liu Y; Wang K; Wang Z; Zhang C; Zhang W; Zhao Z; Li G; Huang L; Chang Y; Zeng F; Jiang T; Hu H CNS Neurosci Ther; 2021 May; 27(5):617-628. PubMed ID: 33645009 [TBL] [Abstract][Full Text] [Related]
4. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938 [TBL] [Abstract][Full Text] [Related]
5. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659 [TBL] [Abstract][Full Text] [Related]
6. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. International Cancer Genome Consortium PedBrain Tumor Project Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748 [TBL] [Abstract][Full Text] [Related]
7. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. Zeng AL; Yan W; Liu YW; Wang Z; Hu Q; Nie E; Zhou X; Li R; Wang XF; Jiang T; You YP Oncogene; 2017 Sep; 36(38):5369-5381. PubMed ID: 28504721 [TBL] [Abstract][Full Text] [Related]
8. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324 [No Abstract] [Full Text] [Related]
9. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451 [TBL] [Abstract][Full Text] [Related]
10. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443 [TBL] [Abstract][Full Text] [Related]
11. Aberrant Al-Ghabkari A; Huang B; Park M Cells; 2024 Jan; 13(3):. PubMed ID: 38334610 [TBL] [Abstract][Full Text] [Related]
12. Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. Chen BS; Wang KY; Yu SQ; Zhang CB; Li GZ; Wang ZL; Bao ZS Oncol Lett; 2020 Nov; 20(5):187. PubMed ID: 32952656 [TBL] [Abstract][Full Text] [Related]
15. Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. Chai RC; Liu X; Pang B; Liu YQ; Li JJ; Li YF; Zhao Z; Du J; Bao ZS; Jiang T Cancer Sci; 2022 Feb; 113(2):796-801. PubMed ID: 34812554 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888 [TBL] [Abstract][Full Text] [Related]
18. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. Le Rhun E; Chamberlain MC; Zairi F; Delmaire C; Idbaih A; Renaud F; Maurage CA; Grégoire V CNS Oncol; 2015; 4(6):381-6. PubMed ID: 26498130 [TBL] [Abstract][Full Text] [Related]
19. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
20. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]